vs
INNOSPEC INC.（IOSP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是INNOSPEC INC.的1.7倍（$772.1M vs $455.6M），Revvity净利率更高（12.7% vs 10.4%，领先2.3%），Revvity同比增速更快（5.9% vs -2.4%），Revvity自由现金流更多（$161.8M vs $46.8M），过去两年Revvity的营收复合增速更高（9.0% vs -4.6%）
Innospec Inc.是一家美国特种化学品企业，前身为奥克泰尔公司及联合奥克泰尔有限公司，旗下设有三大业务板块：高性能化学品业务覆盖个人护理、家居护理、农化、采矿及工业市场；燃料特种化学品业务专注于生产和供应燃油添加剂；油田服务业务则提供钻井、完井及采油相关化学品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
IOSP vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$455.6M
营收增速更快
RVTY
高出8.3%
-2.4%
净利率更高
RVTY
高出2.3%
10.4%
自由现金流更多
RVTY
多$115.0M
$46.8M
两年增速更快
RVTY
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $455.6M | $772.1M |
| 净利润 | $47.4M | $98.4M |
| 毛利率 | 28.0% | — |
| 营业利润率 | 10.3% | 14.5% |
| 净利率 | 10.4% | 12.7% |
| 营收同比 | -2.4% | 5.9% |
| 净利润同比 | 167.3% | 3.9% |
| 每股收益（稀释后） | $1.90 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IOSPRVTY
| Q4 25 | $455.6M | $772.1M | ||
| Q3 25 | $441.9M | $698.9M | ||
| Q2 25 | $439.7M | $720.3M | ||
| Q1 25 | $440.8M | $664.8M | ||
| Q4 24 | $466.8M | $729.4M | ||
| Q3 24 | $443.4M | $684.0M | ||
| Q2 24 | $435.0M | $691.7M | ||
| Q1 24 | $500.2M | $649.9M |
净利润IOSPRVTY
| Q4 25 | $47.4M | $98.4M | ||
| Q3 25 | $12.9M | $46.7M | ||
| Q2 25 | $23.5M | $53.9M | ||
| Q1 25 | $32.8M | $42.2M | ||
| Q4 24 | $-70.4M | $94.6M | ||
| Q3 24 | $33.4M | $94.4M | ||
| Q2 24 | $31.2M | $55.4M | ||
| Q1 24 | $41.4M | $26.0M |
毛利率IOSPRVTY
| Q4 25 | 28.0% | — | ||
| Q3 25 | 26.4% | 53.6% | ||
| Q2 25 | 28.0% | 54.5% | ||
| Q1 25 | 28.4% | 56.5% | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | 28.0% | 56.3% | ||
| Q2 24 | 29.2% | 55.7% | ||
| Q1 24 | 31.1% | 54.6% |
营业利润率IOSPRVTY
| Q4 25 | 10.3% | 14.5% | ||
| Q3 25 | 1.3% | 11.7% | ||
| Q2 25 | 7.8% | 12.6% | ||
| Q1 25 | 9.6% | 10.9% | ||
| Q4 24 | 8.8% | 16.3% | ||
| Q3 24 | 10.3% | 14.3% | ||
| Q2 24 | 9.4% | 12.4% | ||
| Q1 24 | 10.1% | 6.8% |
净利率IOSPRVTY
| Q4 25 | 10.4% | 12.7% | ||
| Q3 25 | 2.9% | 6.7% | ||
| Q2 25 | 5.3% | 7.5% | ||
| Q1 25 | 7.4% | 6.4% | ||
| Q4 24 | -15.1% | 13.0% | ||
| Q3 24 | 7.5% | 13.8% | ||
| Q2 24 | 7.2% | 8.0% | ||
| Q1 24 | 8.3% | 4.0% |
每股收益（稀释后）IOSPRVTY
| Q4 25 | $1.90 | $0.86 | ||
| Q3 25 | $0.52 | $0.40 | ||
| Q2 25 | $0.94 | $0.46 | ||
| Q1 25 | $1.31 | $0.35 | ||
| Q4 24 | $-2.80 | $0.77 | ||
| Q3 24 | $1.33 | $0.77 | ||
| Q2 24 | $1.24 | $0.45 | ||
| Q1 24 | $1.65 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.5M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IOSPRVTY
| Q4 25 | $292.5M | $919.9M | ||
| Q3 25 | $270.8M | $931.4M | ||
| Q2 25 | $266.6M | $991.8M | ||
| Q1 25 | $299.8M | $1.1B | ||
| Q4 24 | $289.2M | $1.2B | ||
| Q3 24 | $303.8M | $1.2B | ||
| Q2 24 | $240.2M | $2.0B | ||
| Q1 24 | $270.1M | $1.7B |
股东权益IOSPRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产IOSPRVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.8B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $46.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.3% | 21.0% |
| 资本支出强度资本支出/营收 | 3.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.30× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $88.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流IOSPRVTY
| Q4 25 | $61.4M | $182.0M | ||
| Q3 25 | $39.3M | $138.5M | ||
| Q2 25 | $9.3M | $134.3M | ||
| Q1 25 | $28.3M | $128.2M | ||
| Q4 24 | $25.7M | $174.2M | ||
| Q3 24 | $73.5M | $147.9M | ||
| Q2 24 | $4.7M | $158.6M | ||
| Q1 24 | $80.6M | $147.6M |
自由现金流IOSPRVTY
| Q4 25 | $46.8M | $161.8M | ||
| Q3 25 | $25.0M | $120.0M | ||
| Q2 25 | $-3.7M | $115.5M | ||
| Q1 25 | $19.9M | $112.2M | ||
| Q4 24 | $13.6M | $149.8M | ||
| Q3 24 | $65.8M | $125.6M | ||
| Q2 24 | $-6.2M | $136.6M | ||
| Q1 24 | $69.9M | $129.7M |
自由现金流率IOSPRVTY
| Q4 25 | 10.3% | 21.0% | ||
| Q3 25 | 5.7% | 17.2% | ||
| Q2 25 | -0.8% | 16.0% | ||
| Q1 25 | 4.5% | 16.9% | ||
| Q4 24 | 2.9% | 20.5% | ||
| Q3 24 | 14.8% | 18.4% | ||
| Q2 24 | -1.4% | 19.7% | ||
| Q1 24 | 14.0% | 20.0% |
资本支出强度IOSPRVTY
| Q4 25 | 3.2% | 2.6% | ||
| Q3 25 | 3.2% | 2.6% | ||
| Q2 25 | 3.0% | 2.6% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 2.6% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.5% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率IOSPRVTY
| Q4 25 | 1.30× | 1.85× | ||
| Q3 25 | 3.05× | 2.97× | ||
| Q2 25 | 0.40× | 2.49× | ||
| Q1 25 | 0.86× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.20× | 1.57× | ||
| Q2 24 | 0.15× | 2.87× | ||
| Q1 24 | 1.95× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IOSP
| Refinery And Performance | $147.0M | 32% |
| Personal Care | $99.7M | 22% |
| Oilfield Services | $93.1M | 20% |
| Other Fuel Specialties | $47.1M | 10% |
| Other Performance Chemicals | $40.0M | 9% |
| Home Care | $28.7M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
